Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly v...
Moderna, Inc. Common Stock (MRNA) has a valuation score of 40/100 (weak), profitability score of 50/100 (moderate), financial health score of 100/100 (strong), Piotroski F-Score of 3/9, Altman Z-Score of 8.72 (safe zone), revenue growth of -53.4% YoY.
Neutral
Analyst Consensus
HoldWall Street consensus estimates — not a PMP forecast · Updated Sep 3, 2026
Analyst Recommendations30 analysts · 2026-09-01
4
7
17
2
Strong Buy 4Buy 7Hold 17Sell 2Strong Sell 0
Recent Market Moves
See all MRNA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Aug 26 | Regular | $148.53 | -6.48% | -4.32 |
| Aug 25 | Pre-market | $143.60 | +3.39% | 2.26 |
| Aug 25 | Regular | $158.63 | +14.21% | 9.48 |
| Aug 25 | After-hours | $158.51 | +14.13% | 9.42 |
| Aug 24 | Regular | $139.43 | -3.93% | -2.62 |